• Updated

(Chalkboard Review) – More than a year after the COVID-19 lockdowns, several major metropolitan school districts across the country are reporting record-level spending per student while enrollment dwindles. New York City, Chicago, Washington D.C., and Los Angeles have increased per student budget expenses in the last five years while academic outcomes have fallen considerably.

  • Updated

FRIDAY, Sept. 30, 2022 (HealthDay News) -- Rubella elimination is likely to be achievable in all countries, but measles elimination is likely in only some countries, according to a study published in the October issue of The Lancet Global Health.

  • Updated

FRIDAY, Sept. 30, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.

  • Updated

FRIDAY, Sept. 30, 2022 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bound to stir new questions, with some doubting the strength of data supporting its effectiveness. Patient advocate groups had strongly lobbied the FDA for its approval, however.

Local & Social